Introduction:To gain insights into the needs, attitudes, perceptions, and preferences of people living with obesity using an online bulletin board (OBB) study. Methods: The OBB is a moderated asynchronous online qualitative market research method that allows interactive discussion among participants. Participants were recruited via physician referral followed by screening questions to ensure eligibility and willingness to participate. The discussions in the OBB were moderated and allowed anonymized open answers and responses. Analysis was performed using various qualitative analytical tools. Results: This OBB study included 23 participants (n = 11, UK; n = 12, USA). Participants expressed negative emotions associated with Enhanced Digital Features To view enhanced digital features for this article go to https://doi.org/10.6084/ m9.figshare.7660616.

OBJECTIVES: This qualitative online bulletin board (OBB) was conducted to gain insights into the needs, perceptions, attitudinal drivers and preferences of people living with obesity. METHODS: OBB is an asynchronous, online, qualitative tool that allows participants to comprehensively answer pre-defined questions. Patients were recruited via physician referral and undertook screening questions to ensure eligibility and willingness to participate. The discussion was moderated and structured and allowed open answers and responses to other participants' posts. Analysis was conducted using a combination of various qualitative analytical tools. RESULTS: The OBB was conducted for four days with 23 participants (11, UK; 12, USA), aged 35e65 years, with body mass index ranging from 30e39. The key insights were: (i) participants have negative emotions associated with their appearance; (ii) obesity has an impact on their social, sexual and work life and the feeling of loneliness causes food indulgence, especially during the evenings; (iii) appearance is the primary cause of anxiety while health is secondary; (iv) they understand the importance of weight reduction, but feel trapped in a 'cycle' where food is abused to overcome physical and emotional problems associated with being obese; (v) participants are not optimistic about weight-management measures (diet/exercise/medication) due to unsuccessful attempts and are apprehensive of trying out new measures and receive little/no support from healthcare providers, friends and family for weight-management; (vi) they prefer medications that would allow them to maintain their current lifestyle but cause visible weight reduction; (vii) along with medication, participants have a strong preference for an online support group with similar participants for motivation, support, adherence and sustained outcomes. CONCLUSIONS: As weight gain is a continuous process and losing excess weight is seen as a challenge, the qualitative insights from this OBB can be used for planning and successful execution of various weight-management programs.

1.04-1.68), >12 to 18 (HR 1.17, 95% CI 1.10-1.83), and >18 (HR 1.21, 95% CI 1.26-2.03) month intervals had elevated risk for CVD (p for trend <0.001). In total strokes, the risk-increasing effect of CVD with longer lipid testing interval is stronger than MI or CHD and this positive association was preserved among subgroups according to drug adherence and outpatient department visits. CONCLUSIONS: Lipid testing intervals of more than 6 months may lead to increased risk of CVD among newly diagnosed dyslipidemia patients. Newly diagnosed dyslipidemia patients should be encouraged to check lipid profile at 6 months interval in order to reducing risk for CVD. OBJECTIVES:To assess the value of implementation of pharmaceutical care (PC) for cardiovascular diseases in low-middle-income countries (LMICs). METHODS: This is a health care use and policy study based on health care management, which has evaluated the value of implementation (VOI) of PC from a societal and Brazilian Public Health System (BPHS) perspective. During 2009, a PC program enlisted 104 patients covered by the BPHS. Direct medical and non-medical costs and social costs were considered. Markov modeling projected over 10-years systemic arterial hypertension complications (ischemic heart disease, stroke, peripheral arterial disease, heart failure, chronic kidney disease). The treatment effect was calculated by comparing PC and conventional care and discount rates of 5% and 3% were applied to costs/outcomes, respectively. In a cash flow model, the net present value based on the return on investment (ROI) over 10 years was calculated, which represented a quantitative measure of the pharmaceutical care (PC) acceptance effect, and was converted into a net health benefit (NHB). The systematizing of the epidemiological and NHB impact provided the calculation and sensitivity analysis of VOI according to the variation for 10,000 Monte Carlo's iterations of 38 inputs from the expected value of PC implementation. RESULTS: The ROI was USD $1,712,710 (95%CI 1,146,000-2,216,000), which represented a cost-benefit ratio of 30.03 (95%CI, 26.74e34.28). The social variables presented an important impact on NHB, they were able to change the ROI from USD $1,283,206 to USD $1,962,401. Lambda was estimated as the largest limit of willingness to pay for QALY, usually in LMICs; in Brazil it is three times the GDP, USD $28,000. Thus, the calculated NHB was 2.8 per patient (95%CI 2.67 -3.04) and NHB ROI¼5.41%. CONCLUSIONS: The impact of implementation was higher than implementation of net beneficial technology, which presents a great opportunity cost for PC.